Novartis has announced plans to acquire Tourmaline Bio for $48.00 per share in cash, totaling approximately $1.4 billion. The acquisition is expected to be completed in the fourth quarter of 2025. Tourmaline’s pacibekitug, a long-acting anti-IL-6 monoclonal antibody, shows promise for treating cardiovascular diseases. Novartis aims to address the role of inflammation in cardiovascular diseases with this acquisition. The transaction has been unanimously approved by both companies’ Boards of Directors. Tourmaline will continue to operate separately until the completion of the transaction.

Pacibekitug, Tourmaline’s lead asset, is a fully-human monoclonal antibody with best-in-class potential. The antibody has a long half-life, low immunogenicity, and high affinity to IL-6, making it a promising treatment for cardiovascular diseases. Novartis President, Shreeram Aradhye, highlights the importance of addressing inflammatory risk in cardiovascular diseases. The transaction is subject to regulatory approvals and certain closing conditions, with completion expected in the fourth quarter of 2025. Novartis plans to diversify its efforts in cardiovascular care through this acquisition.

Read more at GlobeNewswire: Tourmaline Bio Enters into Agreement to be Acquired by